Chou Roger, Helfand Mark
Oregon Evidence-based Practice Center, Oregon Health & Science University, and Portland Veterans Affairs Medical Center, Portland, Oregon, USA.
Ann Intern Med. 2005 Jun 21;142(12 Pt 2):1090-9. doi: 10.7326/0003-4819-142-12_part_2-200506211-00009.
An evidence synthesis of a medical intervention should assess the balance of benefits and harms. Investigators performing systematic reviews of harms face challenges in finding data, rating the quality of harms reporting, and synthesizing and displaying data from different sources. Systematic reviews of harms often rely primarily on published clinical trials. Identifying important harms of treatment and quantifying the risk associated with them, however, often require a broader range of data sources, including unpublished trials, observational studies, and unpublished information on published trials submitted to the U.S. Food and Drug Administration. Each source of data has some potential for yielding important information. Criteria for judging the quality of harms assessment and reporting are still in their early stages of development. Investigators conducting systematic reviews of harms should consider empirically validating the criteria they use to judge the validity of studies reporting harms. Synthesizing harms data from different sources requires careful consideration of internal validity, applicability, and sources of heterogeneity. This article highlights examples of approaches to methodologic issues associated with performing systematic reviews of harms from 96 Evidence-based Practice Center evidence reports.
对医学干预措施的证据综合应评估其利弊平衡。进行危害系统评价的研究人员在查找数据、评估危害报告的质量以及综合和展示来自不同来源的数据方面面临挑战。危害的系统评价通常主要依赖已发表的临床试验。然而,识别治疗的重要危害并量化与之相关的风险,往往需要更广泛的数据来源,包括未发表的试验、观察性研究以及提交给美国食品药品监督管理局的已发表试验的未公开信息。每种数据来源都有产生重要信息的潜力。判断危害评估和报告质量的标准仍处于发展的早期阶段。进行危害系统评价的研究人员应考虑对他们用于判断危害报告研究有效性的标准进行实证验证。综合来自不同来源的危害数据需要仔细考虑内部有效性、适用性和异质性来源。本文重点介绍了与进行危害系统评价相关的方法学问题的方法示例,这些示例来自96份循证实践中心的证据报告。